Clinical Trials Browser

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT04967196 2024-12-10

Ipilimumab and Nivolumab for the Treatment of Stage III-IV Unresectable Metastatic Melanoma

Phase 1 Terminated

6 enrolled

Dermatologic

Melanoma

NCT01738139 2024-03-21

Ipilimumab and Imatinib Mesylate in Advanced Cancer

Phase 1 Completed

68 enrolled

DermatologicGastrointestinalSarcoma

Melanoma, Neoplasm Metastasis, Gastrointestinal Stromal Tumors

NCT01769222 2024-01-24

Ipilimumab and Local Radiation for Selected Solid Tumors

Phase 1 Terminated

3 enrolled 5 charts

DermatologicGastrointestinalLymphoidOther hematologic neoplasm

Burkitt Lymphoma, Colonic Neoplasms, Immunoblastic Lymphadenopathy, Leukemia, Hairy Cell, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Melanoma, Mycosis Fungoides, Rectal Neoplasms, Sezary Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Leukemia, Large Granular Lymphocytic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell, Intraocular Lymphoma

NCT01940809 2022-03-10

Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery

Phase 1 Terminated

15 enrolled

Dermatologic

Melanoma

NCT03425461 2021-04-02

Anti-SEMA4D Monoclonal Antibody VX15/2503 With Nivolumab or Ipilimumab in Treating Patients With Stage III or IV Melanoma

Phase 1 Terminated

6 enrolled

Dermatologic

Melanoma

NCT00039091 2018-09-05

Monoclonal Antibody Therapy in Treating Patients With Ovarian Epithelial Cancer, Melanoma, Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Non-Small Cell Lung Cancer

Phase 1 Terminated

26 enrolled

DermatologicGynecologicMyeloidOther hematologic neoplasmThoracic

Congenital Abnormalities, Carcinoma, Ovarian Epithelial, Carcinoma, Non-Small-Cell Lung, Melanoma, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative

Clinical Trials

Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma

Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers

Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-200M for the Treatment of Melanoma Brain Metastases

Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies

Ipilimumab and Nivolumab for the Treatment of Stage III-IV Unresectable Metastatic Melanoma

Ipilimumab and Imatinib Mesylate in Advanced Cancer

Ipilimumab and Local Radiation for Selected Solid Tumors

Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery

Anti-SEMA4D Monoclonal Antibody VX15/2503 With Nivolumab or Ipilimumab in Treating Patients With Stage III or IV Melanoma

Monoclonal Antibody Therapy in Treating Patients With Ovarian Epithelial Cancer, Melanoma, Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Non-Small Cell Lung Cancer